Back to discover
Disease
Epidermolysis Bullosa
Late-stage therapeutic developmentEmerging research
1
Publications
19
Clinical trials
2020
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2020-03-11The British journal of dermatology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 2 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa
- Q3 2027Evaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fibroblasts) for the Treatment of Wounds Due to Dystropic Epidermolysis Bullosa
Major developments
Major trial resultsHigh impact
Results posted2026-03-18
Upcoming trial readoutHigh impact
Results expected Q3 20272026-03-13
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-03-13Evaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fibroblasts) for the Treatment of Wounds Due to Dystropic Epidermolysis BullosaResults expected Q3 2027
- 2026-03-12A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis BullosaResults expected Q4 2026
Recently completed
- 2026-06-10An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]Primary completion
- 2026-03-01Multi-centeR, Open-label Study to EValuate the Safety, Efficacy, and Pharmacokinetics of FIlsuVEz (Oleogel-S10) in Japanese Subjects With Epidermolysis Bullosa (REVIVE)Primary completion
- 2025-08-29A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB)Primary completion
Activity timeline6
- 2026-06-10ClinicalAn International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]Primary completion
- 2026-03-18ClinicalA Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis BullosaResults posted
- 2026-03-13ClinicalEvaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fibroblasts) for the Treatment of Wounds Due to Dystropic Epidermolysis BullosaResults expected Q3 2027
- 2026-03-12ClinicalA Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis BullosaResults expected Q4 2026
- 2026-03-01ClinicalMulti-centeR, Open-label Study to EValuate the Safety, Efficacy, and Pharmacokinetics of FIlsuVEz (Oleogel-S10) in Japanese Subjects With Epidermolysis Bullosa (REVIVE)Primary completion
- 2025-08-29ClinicalA Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB)Primary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Beremagene geperpavecapproved
Approval — Vyjuvek is indicated for the treatment of wounds in patients with dystroph… (2025)
Clinical trials
The current development programme across all trial phases.
Clinical programme
19
6
15
6
Late-stage studies
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
First approvals
2025emaApproval — Beremagene geperpavec· Vyjuvek is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Major themes1
- Epidermolysis Bullosa1
Leading journals1
- The British journal of dermatology1
Leading researchers8
- Bauer JW1
- Bodemer C1
- Bolling MC1
- Bruckner-Tuderman L1
- Diem A1
- Fine JD1
- Has C1
- Heagerty A1
Affiliations (unnormalised)6
- Bambino Gesù Children's Hospital1
- Birmingham Children's Hospital and University of Birmingham1
- Department of Dermatology and Allergology and EB Haus Austria University Hospital of the Paracelsus Medical University Salzburg1
- Facultad de Medicina Clinica Alemana-Universidad del Desarrollo1
- Great Ormond Street Hospital for Children1
- Heart of England Foundation Trust1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Group of genetically determined disorders characterized by the blistering of skin and mucosae. There are four major forms: acquired, simple, junctional, and dystrophic. Each of the latter three has several varieties.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.